Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead ...

Calcitonin gene-related peptide (CGRP) is a member of the calcitonin family of peptides consisting of calcitonin, amylin, adrenomedullin, adrenomedullin 2 (intermedin) and ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

This program uses two mechanisms of action, targeting the amylin and calcitonin receptors, which are not represented elsewhere in its pipeline so far. That means it isn't just a rehash of its other ...

Amylin helps control blood sugar while calcitonin regulates calcium levels in the blood. William Blair analyst Andy Hsieh noted Viking is also testing a combination of the amylin/calcitonin drug ...

First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...